{"id":"proquazone","rwe":[],"tags":[{"label":"proquazone","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Epidermal growth factor receptor","category":"target"},{"label":"EGFR","category":"gene"},{"label":"PTGS1","category":"gene"},{"label":"PTGS2","category":"gene"},{"label":"M01AX13","category":"atc"},{"label":"Active","category":"status"},{"label":"Analgesics","category":"pharmacology"},{"label":"Analgesics, Non-Narcotic","category":"pharmacology"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Anti-Inflammatory Agents, Non-Steroidal","category":"pharmacology"},{"label":"Antirheumatic Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Cyclooxygenase Inhibitors","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"anthrex","offLabel":[],"synonyms":["proquazone","anthrex","biarison"],"timeline":[],"approvals":[],"brandName":"Anthrex","ecosystem":[],"mechanism":{"target":"Epidermal growth factor receptor, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2","targets":[{"gene":"EGFR","source":"DrugCentral","target":"Epidermal growth factor receptor","protein":"Epidermal growth factor receptor"},{"gene":"PTGS1","source":"DrugCentral","target":"Prostaglandin G/H synthase 1","protein":"Prostaglandin G/H synthase 1"},{"gene":"PTGS2","source":"DrugCentral","target":"Prostaglandin G/H synthase 2","protein":"Prostaglandin G/H synthase 2"}],"modality":"Small Molecule","drugClass":"proquazone","explanation":"Imagine your cells have locks on them, and the Epidermal Growth Factor Receptor is a key that fits into those locks. Proquazone is a small molecule that tries to block the key from fitting into the lock, which could help slow down the growth of certain cells. This is a simplified explanation of how it works at a molecular level.","oneSentence":"Proquazone works by directly interacting with the Epidermal Growth Factor Receptor (EGFR) to potentially inhibit its activity.","technicalDetail":"Proquazone binds to the ATP-binding pocket of the EGFR tyrosine kinase domain, inhibiting its autophosphorylation and subsequent downstream signaling pathways."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2311","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PROQUAZONE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:30:46.223970","biosimilars":[],"competitors":[{"drugName":"nabumetone","drugSlug":"nabumetone","fdaApproval":"1991-12-24","genericCount":14,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"glucosamine","drugSlug":"glucosamine","fdaApproval":"","relationship":"same-class"},{"drugName":"orgotein","drugSlug":"orgotein","fdaApproval":"","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"proquazone","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"nabumetone","brandName":"nabumetone","genericName":"nabumetone","approvalYear":"1991","relationship":"same-class"},{"drugId":"glucosamine","brandName":"glucosamine","genericName":"glucosamine","approvalYear":"","relationship":"same-class"},{"drugId":"orgotein","brandName":"orgotein","genericName":"orgotein","approvalYear":"","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"010966","UNII":"42VPJ2980S","CHEBI":"CHEBI:135151","INN_ID":"3176","UMLSCUI":"C0072247","ChEMBL_ID":"CHEMBL268501","KEGG_DRUG":"D05638","DRUGBANK_ID":"DB13649","PUBCHEM_CID":"31508","MESH_SUPPLEMENTAL_RECORD_UI":"C011385"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"1.27 hours","clearance":"9.45 mL/min/kg","bioavailability":"7%","fractionUnbound":"0.02%","volumeOfDistribution":"0.52 L/kg"},"publicationCount":59,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"M01AX13","allCodes":["M01AX13"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anthrex, also known as Proquazone, is a small molecule. It has multiple synonyms, including 43-715 and Proquazone.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}